论文部分内容阅读
目的:对应用孟鲁司特钠联合布地奈德治疗支气管哮喘的临床疗效进行深入探讨。方法:选取我院收治的104例支气管哮喘患者纳入观察研究中,根据门诊时间随机分成联合组和常规组,每组52例。两组均进行抗感染、平喘化痰、吸氧等治疗,同时常规组单一应用布地奈德治疗,联合组在常规组基础上加用孟鲁司特钠治疗,治疗4周后,对两组患者的肺功能改善、临床疗效进行比较分析。结果:完成治疗后,联合组患者的FVC、FEV_1、FEV1/FVC及PEF等指标均要优于常规组,差异有统计意义(P<0.05);联合组临床总有效率为96.1%,高于常规组的86.2%,有显著性差异(P<0.05);治疗中两组均未出现明显的不良反应。结论:对于支气管哮喘患者,联合应用孟鲁司特钠、布地奈德治疗效果确切,可有效改善患者肺功能,不良反应少,值得临床应用。
Objective: To investigate the clinical efficacy of montelukast combined with budesonide in the treatment of bronchial asthma. Methods: A total of 104 patients with bronchial asthma admitted to our hospital were enrolled in the study. According to the outpatient time, they were randomly divided into the combined group and the conventional group, with 52 cases in each group. Both groups were treated with anti-infective, anti-asthmatic and phlegm, oxygen and other treatment, while the conventional group treated with budesonide alone, combined with montelukast sodium on the basis of the conventional group, after 4 weeks of treatment, Group of patients with improved lung function, clinical efficacy of comparative analysis. Results: After the treatment, the indexes of FVC, FEV_1, FEV1 / FVC and PEF in the combined group were better than those in the conventional group (P <0.05). The total clinical effective rate in the combined group was 96.1% 86.2% of the conventional group, there was a significant difference (P <0.05); no significant adverse reactions in both groups. Conclusion: For patients with bronchial asthma, the combination of montelukast sodium and budesonide has definite curative effect, which can effectively improve the lung function of patients with less adverse reactions and is worthy of clinical application.